Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

References

Page 1

	Year	Citations
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. David Cella, David S. Tulsky, Geoffrey V. Gray, Journal of Clinical Oncology	1993	5.9K
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer I. Craig Henderson, Donald A. Berry, George D. Demetri, Journal of Clinical Oncology	2003	1.3K
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer Joseph A. Sparano, Molin Wang, Silvana Martino, New England Journal of Medicine	2008	1K
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20 Tjeerd J. Postma, Neil K. Aaronson, Jan J. Heimans, European Journal of Cancer Quality Of LifeHealth SciencesPain MedicineSymptomatic TreatmentNeuropathic Pain	2005	559
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer Stephen E. Jones, Michael A. Savin, Frankie A. Holmes, Journal of Clinical Oncology	2006	537
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial Stefano Cascinu, Vincenzo Catalano, L. Cordella, Journal of Clinical Oncology	2002	415
Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J. M. Goldberg, Ulf Lindblom Journal of Neurology Neurosurgery & Psychiatry Haptic FeedbackNeuropsychologyVibration Perception ThresholdNeurological InvestigationHaptic Technology	1979	408
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy Elizabeth A. Calhoun, E. E. Welshman, Chih-Hong Chang, International Journal of Gynecological Cancer	2003	363
Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy Ravi D. Rao, John C. Michalak, Jeff A. Sloan, Cancer	2007	353
Measuring the side effects of taxane therapy in oncology David Cella, Amy H. Peterman, Stacie Hudgens, Cancer	2003	282

Page 1